# US 2024/0392252 A1 · Generating cardiac progenitor cells from pluripotent stem cells using isoxazole or isoxazole like compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0392252 A1
- Document ID: US20240392252A1
- Status: Published application
- Kind: A1
- Application number: 18/634,833
- Filed: 2024-04-12
- Published: 2024-11-28
- Earliest claimed: 2014-04-17
- Assignees: IPS Heart
- Applicants: Ips Heart
- Inventors: Muhammad Ashraf
- Web page: https://patentgrep.com/patent/US20240392252A1

## CPC

- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 35/34: Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44)
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 5/0657: {Cardiomyocytes; Heart cells}
- C12N 5/0658: {Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts}
- C12N 5/0661: {Smooth muscle cells}
- C12N 5/069: {Vascular Endothelial cells}
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/16: Activin; Inhibin; Mullerian inhibiting substance
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This disclosure provides a chemically modified induced pluripotent stem (iPS) cell derived from parental cells and methods for generating the chemically induced pluripotent stem (iPS) cells, as well as cardiac progenitor cells capable of producing cells of multiple sub-lineages. The iPS cells are useful in method for or regenerating cardiac muscle tissue or to promote the replacement of cardiac scar tissue or to rejuvenating cardiac muscles in a patient in need thereof and to treat cardiac disease.

## Claims

### Claim 1

A method of repairing cardiac tissue, said method comprising:
culturing induced pluripotent stem cells (iPSCs) or pluripotent stem cells (PSCs) in a medium without insulin and with isoxazole or isoxazole-9 in an amount effective to induce differentiation for 3-7 days and then culturing in said medium with insulin and without said isoxazole or isoxazole-9 for 7-10 days to produce cardiac progenitor cells or cardiomyocytes; and
injecting said cardiac progenitor cells or cardiomyocytes, or progeny thereof, into damaged cardiac tissue of a heart of a human patient in an amount sufficient for cardiac tissue repair.

### Claim 2

A method of preparing cells for repair of cardiac tissue, said method comprising:
culturing induced pluripotent stem cells (iPSCs) or pluripotent stem cells (PSCs) in a medium without insulin and with isoxazole or isoxazole-9 in an amount effective to induce differentiation for 3-7 days and then culturing in said medium with insulin and without said isoxazole or isoxazole-9 for 7-10 days to produce cardiac progenitor cells or cardiomyocytes.

### Claim 3 (depends on 2)

The method of claim 2, further comprising culturing said cardiac progenitor cells or cardiomyocytes to expand the cardiac progenitor cells or cardiomyocytes.

### Claim 4 (depends on 2)

The method of claim 2, further comprising culturing said cardiac progenitor cells or cardiomyocytes with i) insulin, or ii) TGFB1 and PDGFBB, or iii) EGM to induce further differentiation into cardiomyocytes, smooth muscle cells, or endothelial cells.

### Claim 5 (depends on 2)

The method of claim 2, wherein said iPSCs or PSCs are iPSCs made by treating human adult somatic cells with a DNA methyltransferase inhibitor in an amount sufficient to elevate OCT4, as compared with untreated human adult somatic cells.

### Claim 6 (depends on 2)

The method of claim 2, wherein said iPSCs or PSCs are iPSCs made by treating human adult somatic cells from skeletal muscle with a DNA methyltransferase inhibitor in an amount sufficient to elevate OCT4, as compared with untreated human adult somatic cells.

### Claim 7 (depends on 2)

The method of claim 2, wherein said method excludes insertion of any exogenous gene into said human parent cells.

### Claim 8 (depends on 2)

The method of claim 2, wherein said cardiac progenitor cells or cardiomyocytes are characterized by:
i) over-expression of Nkx-2.5;
ii) decreased expression of one or more pluripotency genes selected from a miR-290-295 cluster, let-7 family, and Max; and
iii) underexpression of Dnmt1 and Dnmt3b, as compared with untreated iPSCs or PSCs.

### Claim 9 (depends on 2)

The method of claim 2, wherein step a) uses 0.1-30 μM of isoxazole or isoxazole-9.

### Claim 10 (depends on 2)

The method of claim 2, wherein said cardiac progenitor cells or cardiomyocytes are characterized by:
i) overexpression of Nkx-2.5 and one or more cardiac markers selected from ISL1, GATA4, ΔMHC, sarcomeric actin, Gαi, mir-133 mir-762 CCL7, CXCR2, CXC5, integral membrane protein 2A, and ephrin A3,
ii) underexpression of one or more pluripotency markers selected from a miR-290-295 cluster, let-7 family, Dnmt1, Dnmt3b, and Max, and
iii) underexpression of one or more DNA methyltransferase genes, each as compared with untreated iPSCs or PSCs.

### Claim 11

A population of cardiac progenitor cells or cardiomyocytes, characterized by:
i) overexpression of Nkx-2.5 and one or more cardiac markers selected from ISL1, GATA4, ΔMHC, sarcomeric actin, Gαi, mir-133 mir-762 CCL7, CXCR2, CXC5, integral membrane protein 2A, and ephrin A3,
ii) underexpression of one or more pluripotency markers selected from a miR-290-295 cluster, let-7 family, Dnmt1, Dnmt3b, and Max, and
iii) underexpression of one or more DNA methyltransferase genes, each as compared with untreated iPSCs or PSCs.

### Claim 12 (depends on 2)

A population of cardiac progenitor cells or cardiomyocytes, produced by the process of claim 2.
